Zinc Nutritional Status in Patients with Cystic Fibrosis

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Marlene Fabiola Escobedo Monge	--	3737	2023-01-18 16:54:57	\|
2	format	Jason Zhu	Meta information modification	3737	2023-01-19 02:49:02	\|

This entry is adapted from the peer-reviewed paper 10.3390/nu11010150

Zinc is an essential nutrient for all forms of life and its deficiency affects the normal growth and development of human beings. Zinc deficiency can be both inherited and acquired. Although severe zinc deficiency is extremely uncommon in European populations, marginal deficiency may be much more prevalent and is associated with immune system dysfunction and restricted physical development. Serum zinc concentration (SZC) was associated with the nutritional status, expressed as BMI (Body Mass Index) and weight-for-height score, and dietary zinc intake with energy intake and weight-for-height score. No patient with hypozincemia had dietary zinc deficiency.

serum zinc concentration hypozincemia dietary zinc intake dietary zinc deficiency

1. Introduction

Cystic fibrosis is a chronic autosomal recessive disorder that affects the lungs and the digestive system of approximately 70,000 people worldwide and is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene ^[1]. Nearly 2000 different disease-causing mutations have been identified, but the most common mutation (approximately 70% of patients) is a three-base-pair deletion (CTT) in exon 10. This mutation causes an in-frame deletion of a phenylalanine residue (DF508) and it results in the lack of a functional cAMP-gated chloride channel on the apical surface of secretory epithelial cells ^[2]. Thus, CF epithelia fail to transport chlorine and water, and morbidity in CF often results from lung disease ^[3]. The gastrointestinal manifestations of CF include exocrine pancreatic insufficiency and intestinal mucosal abnormalities ^[4]. The incidence of CF is about one in 3500 white births in Europe. The mean prevalence in the United States and de European Union (EU) is similar, 0.74 and 0.80 in 10,000 people, respectively ^[1]. Growth and development in patients with CF can be impacted by several factors that are associated with the disease, such as nutritional status and zinc in particular.

The solution and complexation chemistry of zinc ions is the basis for zinc biology ^[5]. Zinc is a ubiquitous trace element ^[6]^[7]. Zinc is the 23rd most abundant element in the earth’s crust ^[8], having atomic number 30 and atomic weight 65.37, is vital in the living world ^[9]. Zinc is an essential trace element that participates in many metabolic processes as a catalytic, regulatory, and structural component ^[10]. It is a vital cofactor for the function of more than 10% of proteins that are encoded by the human genome (approximately 3000 proteins/enzymes) ^[11]^[12]). Zinc-dependent proteins play numerous indispensable roles within cells, such as transcriptional regulation, DNA repair, apoptosis, metabolic processing, extracellular matrix (ECM) regulation, and antioxidant defence ^[13]. It is also involved in the metabolic hormone regulation of growth and it has key roles in gene expression regulation and the immune system. Zinc also regulates thousands of genes through the metal response element (MRE) binding transcription factor-1 (MTF-1), and zinc controls numerous cell-signalling pathways by modulating kinase and phosphorylase activities. The coordination of these zinc-dependent cellular functions appears to be related to one or several of the 24 zinc transporters that exhibit differing specificity of expression in different cell types ^[14]^[15].

Zinc is important for human health and disease due to its critical roles in growth and development ^[6]^[7], bone metabolism, the central nervous system, immune function, and wound healing ^[16]. Not only in physiological but also mental and behavioral terms ^[17]. Zinc is essential for a wide variety of cellular processes in all cells ^[18]. Cells with a rapid rate of turnovers, such as those of immune, gastrointestinal systems, and skin, are particularly vulnerable to zinc deficiency, accounting for the initial effects of dermatitis, diarrhoea, alopecia, and loss of appetite ^[19]. Zinc deficiency impairs both the specific susceptibility to bacterial, viral, and fungal pathogens ^[20]. This triggers an array of health problems in children, many of which can become chronic and serious, such as weight loss, stunted growth, weakened resistance to infections, and early death ^[21]. The early effects of zinc deficiency are chemical, functional, and may be “hidden”. Some examples of functions at risk are: gene expression, fetal growth and development, child and adolescent growth, wound healing, immunity, resistance to oxidative stress and inflammation, brain development, and neuropsychological function ^[22].

2. Zinc Deficiency in in Patients with Cystic Fibrosis

There is a strong plausibility for zinc deficiency in infants and children with CF. Zinc deficiency has been documented in young infants identified by newborn screening prior to the initiation of pancreatic enzyme therapy ^[4]. In settings without newborn screening, the presentation is typically later in infancy, with associated growth faltering, diarrhoea, and dermatitis similar to acrodermatitis enteropathica ^[23]. Investigators have examined the relationship between zinc, body composition, growth, and pulmonary function in older children and adults with CF after the original report by Halsted and Smith in 1970 ^[24]. Nowadays, the use of zinc-finger nucleases to permanently and precisely modify the human genome offers a potential alternative to cDNA-based gene therapy in subjects with CF ^[2]. In Spain and in the EU there are few studies of zinc nutritional status in CF patients.

Zinc, an almost omnipresent metal ion, is not only a vital element in various physiological processes but also a drug in the prevention and management of many diseases. Nearly half of the world’s population is at risk for inadequate zinc intake, suggesting that public health programs are urgently needed to control zinc deficiency. The inability to link the physiological effects of zinc depletion to zinc status is due, in part, to an incomplete understanding of the biochemical and physiologic functions of zinc ^[10]. Zinc’s anticopper action is unique ^[25]. A moderate level of zinc deficiency has been observed in many gastrointestinal disorders. These include malabsorption syndrome, Crohn’s disease, regional ileitis, and steatorrhea. In 1968, MacMahon et al. ^[26] were the first to report zinc deficiency in a patient who had steatorrhea. Zinc deficiency in patients with malabsorption syndrome is now well recognized, and most physicians are aware of this problem ^[27].

The lack of generally accepted biomarkers of zinc status has further impeded the estimation of the global prevalence of zinc deficiency ^[25]. No single body zinc compartment represents an adequate estimate of overall body zinc status ^[28]^[29]. The normal concentration of zinc in human blood serum and urine (24 h) is 800 ± 200, 109 to 130, and <500 μg/dL, respectively. The mean serum zinc concentration is 1 mg/L ^[30]. Red blood cells contain about 10 times higher concentration than that in the serum. Whole blood has about five times the serum concentration ^[31]. A thorough assessment of zinc status by current methods is complex. For now, the simplest measure is plasma zinc, which is 71% sensitive for clinically apparent deficiency ^[32], at a cutoff of 40 mg/dL ^[33]. It is insensitive for marginal (subclinical) deficiency. Thus, it is difficult to identify zinc deficiency in association with acute diarrhoea and to know how to monitor efficacy of replacement in terms of zinc nutrition ^[7].

A sensitive, specific biomarker of zinc nutrition has not been identified for the individual diagnosis of zinc deficiency. The most commonly used measurement of zinc status is plasma or serum zinc, despite the fact that less than 0.1% of body zinc is present in plasma and the concentration appears to be under strict homeostatic control. Despite these limitations, the fact that plasma zinc concentrations are normally distributed in healthy populations makes it possible to establish reference values to be used to identify individuals at risk for a low zinc status ^[34]. Therefore, plasma or serum zinc concentration is the only biochemical indicator to assess the zinc status of populations recommended by WHO/UNICEF/IAEA/IZiNCG ^[28].

Borowitz et al. point out that hypozincemia in CF is difficult to characterize, because zinc deficiency may be present when plasma zinc is in the normal range ^[35]. In a study, increased zinc loss in 101 patients (mean age 16 years) with persisting steatorrhea was found, and 12.6% of this population had SZC below the p-value of 2.5 of the NHANES II, so there could have an increased risk of zinc deficiency in some CF patients ^[36]. Although hypozincemia has been reported in approximately 30% of young infants with CF in newborns screenings ^[37], Maqbool et al. reveal that prevalence of low plasma zinc ranging from 0% to 40% in various populations of infants, children, and adolescents with CF ^[38]. There have been several reports of young infants with CF presenting with signs and symptoms of severe zinc deficiency ^[39], such as growth retardation, increased susceptibility to infections, delayed sexual maturation, eye problems, and anorexia that are caused by a reduced sense of taste (hypogeusia) ^[1].

However, many studies have shown that zinc plays a role in promoting physical growth and the development of intelligence in children ^[40]. Young children are at greater risk of zinc deficiency because of increased zinc requirements during growth. Exclusively breastfed infants of mothers with adequate zinc nutriture obtain sufficient zinc for the first 5–6 months of their life ^[41]. Children are particularly sensitive to a suboptimal state of zinc during periods of rapid growth that create a higher need for zinc that may not be met ^[42]. It seems to be that zinc is the most important factor in the needs related to the deposit of new tissue, since 20 mg of zinc are needed for each kg of muscle mass ^[43]. Therefore, a higher growth rate corresponds to higher net zinc retention ^[44]. After this age, complementary foods containing absorbable zinc are required to satisfy their requirements. The physiological requirements for zinc peak during adolescence at the time of the pubertal growth spurt, which generally occurs in girls between 10 years and 15 years and in boys between 12 years and 15 years. Even after the growth spurt has ceased, adolescents may require additional zinc to replenish depleted tissue zinc pools ^[45]. On the other hand, a marginal zinc status during the outbreak of pubertal growth has been associated with slow skeletal growth, maturation, and reduction in bone mineralization ^[28].

Recent studies have demonstrated that a well-balanced diet leads to an improved redox status, which positively affects reducing the risk of non-communicable chronic diseases ^[46]. An inadequate intake of micronutrients at any stage of life affects various functions within the immune system, manifesting in decreased resistance to infections and an increase in the severity of symptoms. For example, zinc deficiency can increase thymic atrophy, decrease lymphocyte number and activity, and increase oxidative stress and inflammation by altering cytokine production ^[47]^[48]. As a result, the risk of all types of infection (bacterial, viral, and fungal), but especially diarrhoea and pneumonia, is increased ^[49].

In spite of the fact that 23.5% of patients had inadequate dietary zinc intake, none of them had hypozincemia (17.6%). Low serum zinc concentrations can occur in the presence of several conditions, representing a normal physiologic response and they are not necessarily indicative of low zinc status ^[11]. Zinc can be temporarily redistributed from plasma to other tissue or the concentrations can be changed by conditions that are unrelated to zinc status. Infections, fever, food intake, and pregnancy lower plasma zinc, whereas starvation and catabolism increase it. Plasma zinc is also depressed at times of rapid tissue growth ^[50]. Cellular, tissue, and whole-body zinc homeostasis are tightly controlled to sustain metabolic functions over a wide range of zinc intakes, making it difficult to assess zinc insufficiency or excess ^[51]. In many moderate zinc dietary restrictions (3–5 mg/day), the response is more inconsistent, with a slight decrease or no change in serum zinc concentrations, possibly related to the duration of the dietary restriction and the relationship phytate:zinc molar ratio from the diet. Serum zinc levels fall clearly when the dietary zinc intake is less than approximately 2 to 3 mg, reaching a plateau when zinc intake reaches approximately 25 to 30 mg/day ^[28]. This means that, in populations with a high prevalence of inadequate zinc intake, there would be a higher prevalence of low serum zinc concentration ^[52]. Thus, the prevalence of low concentrations of serum zinc may be indicative of the risk of zinc deficiency in the population ^[28]^[53].

Those observations are not surprising, because the gastrointestinal manifestations of this common heritable condition include exocrine pancreatic insufficiency and intestinal mucosal abnormalities ^[38], which produces malabsorption of essential fatty acids, fat-soluble vitamins, and several micronutrients, including zinc ^[54]. Increasing evidence demonstrates the importance of zinc in CF-affected tissues including the lungs and pancreas ^[55]. Zinc is particularly abundant in the pancreas, where it is involved in the control of glucagon secretion and digestive enzyme activity. Zinc is very important in the synthesis, storage, and secretion of insulin, as well as in maintaining conformational integrity of insulin in the hexameric form. Any decrease in zinc levels can affect the ability of the islet of Langerhans cell to produce and secrete insulin, and compound the problem, particularly in type II diabetes ^[56]. Therefore, zinc deficiency is associated with decreased insulin secretion and sensitivity, features that are characteristic of CF-related diabetes ^[55].

It should be understood that the major organ system of zinc exchange with the environment is the gut ^[32]^[39]. The current understanding of zinc homeostasis indicates that the primary determinants of zinc absorption are the amount of zinc ingested and dietary phytate, with the latter having a major effect on zinc bioavailability. However, in normal as well as in many pathologic conditions, the gastrointestinal tract is the major site of zinc losses resulting from the secretion of endogenous zinc into the lumen and subsequent excretion in the faeces ^[57]. Zinc is primarily absorbed by a saturable process in the proximal small bowel but also more distally through entero-enteric reabsorption that diminishes losses ^[58]. Two generalized dietary patterns are major factors in the aetiology of dietary zinc deficiency; one in which the inhibition of absorption predominates and bioavailability is the issue and the other in which the zinc content of the diet is deficient ^[59]. The adjustments in gastrointestinal zinc absorption and endogenous excretion are synergistic. Shifts in the endogenous excretion appear to occur quickly with changes in intake just above or below optimal intake, while the absorption of zinc responds more slowly, but it has the capacity to cope with large fluctuations in intake ^[60]. With extremely low zinc intakes or with prolonged marginal intakes, secondary homeostatic adjustments may augment the gastrointestinal changes. These secondary adjustments include changes in urinary zinc excretion, a shift in plasma zinc turnover rates, and possibly, an avid retention of zinc released from selected tissues, such as bone, in other tissues to maintain function ^[61]^[62].

The results showed that some participants still had residual steatorrhea (76.5%), even though all patients except one of them received adequate doses of PERT and fat-soluble vitamins supplements with their diet. The correlation between dietary zinc intake and weight-for-height Z-score was not influenced in the absence of residual steatorrhea. Therefore, patients without PI had a normal weight-for-age Z-score, and there was no correlation significant between them and dietary zinc intake. On the contrary, weight-for-height Z-score had a positive and significant correlation with dietary zinc intake (r = 0.58, p = 0.038) in patients with PI. Weight-for-age was not affected by IP and it was normal in patients with zinc deficiency intake.

Pancreatic insufficiency is frequently present in CF and it causes a major problem for zinc absorption. The fact that zinc deficiency increases the susceptibility to childhood diarrhoea while increased losses of endogenous zinc that are associated with diarrhoea further deplete body zinc, resulting in a vicious cycle that merits further study ^[63]. Recent stable isotope studies have reported increased endogenous faecal zinc losses and decreased zinc absorption in children and infants with CF ^[35]^[57]. Untreated pancreatic insufficiency also increases zinc losses. The fractional zinc absorption is improved by PERT. However, some CF patients continue to have steatorrhea despite correct PERT, and might, therefore, be at risk for developing zinc deficiency. Many CF patients have a suboptimal nutritional status despite the nutritional advice and PERT ^[64]. For infants and children <2 years of age who are not growing despite apparently adequate nutritional intake, a six-month trial of zinc supplementation (1 mg zinc/kg/day) has been recommended ^[35].

Despite treatment with supra-physiological doses of pancreatic enzyme supplements, residual steatorrhoea is a common problem in patients with cystic fibrosis (CF) and pancreatic insufficiency. Strategies to enhance the activity of pancreatic enzymes include decreasing duodenal acidity. Proesmans and Deboec evaluated the effect of omeprazole (Losec), a proton-pump inhibitor, on fat absorption in 15 CF patients (three girls and 12 boys) with confirmed residual steatorrhoea, despite a high dose pancreatic enzyme supplements (Lipase > or =10,000 UI/kg/day). During treatment with omeprazole, median faecal fat loss (g fat/day) decreased from 13 g (quartiles 11.5–16.5 g/day) to 5.5 g (quartiles 4.9–8.1 g/day) (p < 0.01). The same improvement was noted when fat absorption was calculated: 87% (quartiles 81–89%) without versus 94% (quartiles 90–96%) with omeprazole (p < 0.001). They concluded that omeprazole improves fat digestion and absorption in CF patients with residual faecal fat loss despite maximal pancreatic enzyme substitution ^[65]. This improvement could contribute to an increase in zinc absorption. However, suppression of gastric acid secretion by omeprazole reduces intestinal absorption of zinc in other studies ^[66]^[67]. Farrel et al. point out that PPI use dramatically reduces supplemental zinc uptake and it can result in decreased zinc body stores. Certain individuals on long-term PPI therapy, such as infants being treated for colic, may be at risk for decreased systemic levels of trace metals that are needed for developmental, regenerative, and immunological requirements ^[67].

The participants were clinically stable at the time of the study. ERS and CRP were slightly increased in a single patient with hypozincemia (23 mm/h) and zinc intake deficiency (6.9 U/L), respectively. C-reactive protein (CRP) is an acute-phase protein that serves as an early marker of inflammation or infection. The protein is synthesized in the liver and it is normally found at concentrations of less than 10 mg/L in the blood. During infectious or inflammatory disease states, CRP levels rise rapidly within the first 6 to 8 h and peak at levels of up to 350–400 mg/L after 48 h. CRP binds to phosphocholine expressed on the surface of damaged cells, as well as to polysaccharides and peptosaccharides that are present on bacteria, parasites, and fungi. This binding activates the classical complement cascade of the immune system and modulates the activity of phagocytic cells, supporting the role of CRP in the opsonization (i.e., the process by which a pathogen is marked for ingestion and destruction by a phagocyte) of infectious agents and dead or dying cells. When the inflammation or tissue destruction is resolved, the CRP levels fall, making it a useful marker for monitoring disease activity ^[68]. Elevated concentrations of C-reactive protein or other markers of the acute phase response can be used to indicate the presence of infection and should be considered in the interpretation of results ^[69].

Serum zinc concentrations are reduced during acute infections and inflammation ^[70]. Corbo et al. point out that acute stress and inflammation may contribute to zinc redistribution, leading to lower plasma zinc concentrations without affecting total body store ^[71]. Conversely, normal serum levels do not necessarily translate to a sufficient body store of zinc. Zinc deficiency causes thymic atrophy, lymphopenia, and compromised cell- and antibody-mediated responses that increase the rates and duration of infections. Zinc deficiency is characterized by decreased lymphocyte number and function, particularly T cells, increased thymic atrophy, altered cytokine production that contributes to oxidative stress and inflammation ^[47]; increased risk of bacterial, viral, and fungal infections (particularly diarrhea and pneumonia) ^[72] and diarrheal and respiratory morbidity ^[48]^[73]. Contrariwise, its supplementation produces the restoration of thymulin activity, increased numbers of cytotoxic T cells, reduced numbers of activated T helper cells (which can contribute to autoimmunity), increased natural killer cell cytotoxicity, and reduced incidence of infections ^[47]. In children, there is a reduction in the duration of diarrhoea and incidence of pneumonia in at-risk children >6 month, but not in children 2–6 month ^[72]; reduced duration and severity of common cold symptoms; and, improved outcomes in pneumonia, malaria, and diarrheal symptoms ^[49]^[74].

In the airway epithelium, zinc is important for ciliary function, wound healing, and suppression of oxidative stress and apoptosis; all of which have been shown to be impaired in CF. Zinc is known to play a regulatory role in the immune system where correlations have been found between plasma zinc and IL-2 levels, natural killer cell activity, and active thymulin in CF children. Zinc status also affects the expression of proinflammatory cytokines, such as TNFα, IL-1β, and IL-8 ^[55]. Zinc deficiency leads to an increase in oxidative damage in the airways by causing infiltration of inflammatory cells and increases the production of nitric oxide and superoxide. When this deficiency occurs in conjunction with acute damage to the lung or asthma, greater inflammation occurs, increasing the frequencies of hospitalizations ^[54]. According to Ataee et al., the number of hospitalizations was significantly reduced after zinc administration, which could be due to the preventive effect of zinc on pneumonia, which is a major cause of hospitalization in these patients {33]. Zinc, an acute phase reactant, would shorten the duration of severe pneumonia and time in the hospital. Adjuvant treatment with 20 mg zinc per day accelerated recovery from severe pneumonia in children and could help to reduce antimicrobial resistance by decreasing multiple antibiotic exposures and lessen complications and deaths where second-line drugs are unavailable ^[75].

Even though data on zinc supplementation among children with cystic fibrosis are limited ^[37]^[54]^[76]^[77]^[78], the ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adult with CF suggest zinc supplementation for people who are at risk of zinc insufficiency ^[1]. At present, despite contradictory findings, many researchers believe that the intake of 30 mg/day of zinc reduces the number of days of antibiotics used to treat respiratory tract infections in these children ^[54]. The supplementation trial in 13 Swedish children (2–19 years) for six months demonstrated the transient normalization of plasma zinc levels, where all subjects had had low plasma zinc levels at baseline, but growth velocity or lung function did not improve with the normalization of plasma zinc levels ^[78]. However, Borowitz et al. reported that empiric zinc supplementation as a treatment trial for a period of six months can be considered for CF patients who are failing to thrive or that have short stature ^[35].

In spite of the fact that Sharma et al. in a double-blind randomized placebo-controlled, the study of zinc supplementation in 37 children with CF (age 5–15 y) did not find any significant difference in the need for antibiotics, pulmonary function tests, hospitalization, colonization with pseudomonas, or the need for antibiotics. They highlighted that the majority of the children had low serum zinc levels at baseline; therefore, the dose of zinc administered may not have been sufficient to have an impact on the outcomes ^[77]. Conversely, Abdulhamid et al. conducted a double-blind randomized controlled small trial in which 26 children were treated with placebo or zinc (30 mg/day) for one year. They documented that the requirement for antibiotics was significantly lower among those receiving zinc than those receiving placebo (p = 0.05). The improvement was more pronounced among those who had low plasma zinc at baseline (p = 0.02). Reduced levels of plasma interleukin-6 and interleukin-8 were also documented. Furthermore, they recommended that higher daily doses of zinc might be necessary to decrease respiratory tract infections and modify the immune response ^[54].

References

Turck, D.; Braegger, C.P.; Colombo, C.; Declercq, D.; Morton, A.; Pancheva, R.; Robberecht, E.; Stern, M.; Strandvik, B.; Wolfe, S.; et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin. Nutr. 2016, 35, 557–577.
Lee, C.M.; Flynn, R.; Hollywood, J.A.; Scallan, M.F.; Ptrick THarrison, P.T. Correction of the DF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair. BioRes. Open Access 2012, 1, 99–108.
Zsembery, Á.; Fortenberry, J.A.; Liang, L.; Bebok, Z.; Tucker, T.A.; Boyce, A.T.; Braunstein, G.M.; Welty, E.; Bell, P.D.; Sorscher, E.J.; et al. Extracellular Zinc and ATP Restore Chloride Secretion across Cystic Fibrosis Airway Epithelia by Triggering Calcium Entry. J. Biol. Chem. 2004, 279, 10720–10729.
Krebs, N.F.; Sontag, M.; Accurso, F.J.; Hambidge, K.M. Low plasma zinc concentrations in young infants with cystic fibrosis. J. Pediatr. 1998, 133, 761–764.
Krężel, A.; Maret, W. The biological inorganic chemistry of zinc ions. Arch. Biochem. Biophys. 2016, 611, 3–19.
Cousins, R.J. Zinc, 7th ed.; ILSI Press: Washington, DC, USA, 1996.
Young, G.P.; Mortimer, E.K.; Gopalsamy, G.L.; Alpers, D.H.; Binder, H.J.; Manary, M.J.; Ramakrishna, B.S.; Brown, I.L.; Brewer, T.G. Zinc deficiency in children with environmental enteropathy—Development of new strategies: Report from an expert workshop. Am. J. Clin. Nutr. 2014, 100, 1198–1207.
Zinc: Human Health Fact Sheet; Argonne National Laboratory: Chicago, IL, USA, 2005. Available online: http://www.ead.anl.gov/pub/ doc/zinc.pdf (accessed on 6 December 2011).
Contaminants: Zinc; E.B.I.: Environmental Bureau of Investigation: Toronto, ON, Canada, 2002. Available online: http://www.e-b-inet/ebi/ contaminants/zinc.html (accessed on 25 March 2002).
King, J.C.; Brown, K.H.; Gibson, R.S.; Krebs, N.F.; Lowe, N.M.; Siekmann, J.H.; Raiten, D.J. Supplement: Biomarkers of Nutrition for Development (BOND)—Zinc Review. J. Nutr. 2016, 9, 1S–28S.
Roohani, N.; Hurrell, R.; Kelishadi, R.; Schulin, R. Zinc and its importance for human health: An integrative review. J. Res. Med. Sci. 2013, 18, 144–157.
Freeland-Graves, J.H.; Sanjeevi, N.; Lee, J.J. Global perspectives on trace element requirements. J. Trace Elem. Med. Biol. 2015, 31, 135–141.
Lin, P.; Sermersheim, M.; Li, H.; Lee, P.H.U.; Steinberg, S.M.; Ma, J. Zinc in Wound Healing Modulation. Nutrients 2018, 10, 16.
Liuzzi, J.P.; Cousins, R.J. Mammalian zinc transporters. Annu. Rev. Nutr. 2004, 24, 151–172.
Lukacik, M.; Thomas, R.L.; Aranda, J.V. A meta-analysis of the effects of oral zinc in the treatment of acute and persistent diarrhea. Pediatrics 2008, 121, 326–336.
Nussbaum, S.R.; Carter, M.J.; Fife, C.E.; da Vanzo, J.; Haught, R.; Nusgart, M.; Cartwright, D. An economic evaluation of the impact, cost, and medicare policy implications for chronic nonhealing wounds. Value Health 2017.
Morales-Suaréz-Varela, M.; Rubio-López, N.; Ruso, C.; Llopis-Gonzalez, A.; Ruiz-Rojo, E.; Redondo, M.; Pico, Y. Anthropometric Status and Nutritional Intake in Children (6–9 Years) in Valencia (Spain): The ANIVA Study. Int. J. Environ. Res. Public Health 2015, 12, 16082–16095.
Ackland, M.L.; Michalczyk, A.A. Zinc and Nutrition. Arch. Biochem. Biophys. 2016, 611, 51–57.
Aggett, P.J. Zinc in Human Biology; Mills, C.F., Ed.; Springer-Verlag: London, UK, 1989; pp. 259–279.
Ibs, K.H.; Rink, L. Zinc-altered immune function. J. Nutr. 2003, 133, 1452S–1456S.
Salgueiro, M.J.; Zubillaga, M.B.; Lysionek, A.E.; Caro, R.A.; Weill, R.; Boccio, J.R. The role of zinc in the growth and development of children. Nutrition 2002, 18, 510–519.
Sandstead, H.H.; Freeland-Graves, J.H. Dietary phytate, zinc and hidden zinc deficiency. J. Trace Elem. Med. Biol. 2014, 28, 414–417.
Wenk, K.S.; Higgins, K.B.; Greer, K.E. Cystic fibrosis presenting with dermatitis. Arch Dermatol. 2010, 146, 171–174.
Halsted, J.A.; Smith, J.C., Jr. Plasma-zinc in health and disease. Lancet 1970, 1, 322–324.
Kaur, K.; Gupta, R.; Saraf, S.A.; Saraf, S.K. Zinc: The Metal of Life. Compr. Rev. Food Sci. Food Saf. 2014, 13, 358–376.
Raiten, D.J.; Namaste, S.; Brabin, B.; Combs, G.; L’Abbe, M.R.; Wasantwisut, E.; Darnton-Hill, I. Executive summary—Biomarkers of Nutrition for Development: Building a consensus. Am. J. Clin. 2011, 94, 633S–650S.
Prasad, A.S. Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease. Adv. Nutr. 2013, 4, 176–190.
Gibson, R.; Hess, S.; Hotz, C.; Brown, K. The indicators of zinc status in the population: A review of the evidence. Br. J. Nutr. 2008, 99 (Suppl. 3), S14–S23.
de Benoist, B.; Darnton-Hill, I.; Davidsson, L.; Fontaine, O.; Hotz, C. Conclusions of the Joint WHO/UNICEF/IAEA/IZiNCG Interagency Meeting on Zinc Status Indicators. Food Nutr. Bull. 2007, 28 (Suppl. 3), S480–S484.
Goldfrank, L.R.; Flomenbaum, N. Goldfrank’s Toxicologic Emergencies, 8th ed.; McGraw-Hill Professional: New York, NY, USA, 2006; p. 1981.
Noonan, C.W.; Kathman, S.J.; Sarasua, S.M.; White, M.C. Influence of environmental zinc on the association between environmental and biological measures of lead in children. J. Expo. Sci. Environ. Epidemiol. 2003, 13, 318–323.
King, J.C. Zinc: An essential but elusive nutrient. Am. J. Clin. Nutr. 2011, 94, 679S–684S.
Wessells, K.R.; King, J.C.; Brown, K.H. Relationships between plasma zinc concentrations and clinical signs of zinc deficiency. FASEB J. 2014, 28, 1043.9S.
Sandström, B. Diagnosis of zinc deficiency and excess in individuals and populations. Food. Nutr. Bull. 2001, 22, 133–137.
Borowitz, D.; Baker, R.; Stallings, V. Consensus Report on Nutrition for Pediatric Patients with Cystic Fibrosis. J. Pediatr. Gastroenterol. Nutr. 2002, 35, 246–259.
Van Biervliet, S.; Van Biervliet, J.; Bernard, D.; Vercaemst, R.; Blanton, V. Serum zinc in healthy Belgian children. Biol. Trace Elem. 2002, 94, 33–40.
Ataee, P.; Najafi, M.; Gharagozlou, M.; Aflatounian, M.; Mahmoudi, M.; Khodadad, A.; Farahmand, F.; Motamed, F.; Fallahi, G.H.; Kalantari, N.; et al. Effect of supplementary zinc on body mass index, pulmonary function and hospitalization in children with cystic fibrosis. Turk. J. Pediatr. 2014, 56, 127–132.
Maqbool, A.; Schall, J.; Zemel, B.S.; Garcia-Espana, F.; Stallings, V. Plasma Zinc and Growth Status in Preadolescent Children with Cystic Fibrosis. J. Pediatr. Gastroenterol. Nutr. 2006, 43, 95–101.
Krebs, N.; Westcott, J.R.; Arnold, T.D.; Kluger, B.M.; Accurso, F.J.; Miller, L.V.; Hambidge, K.M. Abnormalities in Zinc Homeostasis in Young Infants with Cystic Fibrosis. Pediatr. Res. 2000, 48, 256–261.
Ozbek, N.; Akman, S. A slurry sampling method for the determination of iron and zinc in baby food by flame atomic absorption spectrometry. Food Addit. Contam. Part A 2012, 29, 208–216.
Millán, E.G.; Papale, J.; Berné, Y.; Castro, M.; Moreno, J.M.; Alarcón, O.M.; Torres, M. Valores de referencia de cinc (Zn) y de cobre (Cu) séricos en escolares sanos procedentes de la ciudad de Barquisimeto, Venezuela. Revista del Instituto Nacional de Higiene Rafael Rangel 2012, 43.
Junior, J.; Dean, S.; Mayo-Wilson, E.; Imdad, A. Bhutta Zinc supplementation for preventing mortality and morbidity, and promoting growth, in children aged 6 months to 12 years of age (protocol). Cochrane Database Syst. Rev. 2011.
Giugliano, R.; Millward, D.J. Growth and zinc homeostasis in severely Zn-deficient rat. Br. J. Nutr. 1984, 52, 545–560.
Ruz, M.; Castillo-Duran, C.; Lara, X.; Codoceo, J.; Rebolledo, A.; Atalah, E. A 14-mo zinc-supplementation trial in apparently healthy Chilean preschool children. Am. J. Clin. Nutr. 1997, 66, 1406–1413.
Maret, E.; Sandstead, H. Zinc requirements and the risks and benefits of zinc supplementation. J. Trace Elem. Med. Biol. 2006, 20, 3–18.
Jansen, E.; Ruskovska, T. Serum biomarkers of (anti) oxidant status for epidemiological studies. Int. J. Mol. Sci. 2015, 16, 27378–27390.
Micronutrient Information Center. Immunity in Depth. 2018. Available online: http://lpi.oregonstate.edu/mic/ health-disease/immunity (accessed on 17 April 2018).
Savino, W.; Dardenne, M. Nutritional imbalances and infections affect the thymus: Consequences on T-cell-mediated immune responses. Proc. Nutr. Soc. 2010, 69, 636–643.
Maggini, S.; Pierre, A.; Calder, P.C. Immune Function and Micronutrient Requirements Change over the Life Course. Nutrients 2018, 10, 1531.
Livingstone, C. Zinc: Physiology, deficiency, and parenteral nutrition. Nutr. Clin. Pract. 2015, 30, 371–382.
Prasad, A.S. Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health. Front. Nutr. 2014, 1, 14.
Wessells, K.R.; Brown, K.H. Estimating the global prevalence of zinc deficiency: Results based on zinc availability in national food supplies and the prevalence of stunting. PLoS ONE 2012, 7, e50568.
Wieringa, F.T.; Dijkhuizen, M.A.; Fiorentino, M.; Laillou, A.; Berger, J. Determination of Zinc Status in Humans: Which Indicator Should We Use? Nutrients 2015, 7, 3252–3263.
Abdulhamid, I.; Beck, F.; Millard, S.; Chen, X.; Prasad, A. Effect of Zinc Supplementation on Respiratory Tract Infections in Children with Cystic Fibrosis. Pediatr. Pulmonol. 2008, 43, 281–287.
Damphousee, V.; Mailhot, M.; Berthiaume, Y.; Rabasa-Lhoret, R.; Mailhot, G. Plasma zinc in adults with cystic fibrosis: Correlations with clinical outcomes. J. Trace Elem. Med. Biol. 2014, 28, 60–64.
Chausmer, A. Zinc, insulin and diabetes. J. Am. Coll. Nutr. 1998, 17, 109–115.
Krebs, N.F. Update on zinc deficiency and excess in clinical paediatric practice. Ann. Nutr. Metab. 2013, 62 (Suppl. 1), 19–29.
Alpers, D.H. Intraluminal bioavailability of divalent cations. Curr. Opin. Gastroenterol. 2013, 29, 164–169.
Hambidge, K.M.; Miller, L.V.; Westcott, J.; Sheng, X.; Krebs, N.F. Zinc bioavailability and homeostasis. Am. J. Clin. Nutr. 2010, 91, 1478S–1483S.
King, J.C.; Shames, D.M.; Woodhouse, L.R. Zinc homeostasis in humans. J Nutr. 2000, 130, 1360S–1366S.
Brown, K.H.; Rivera, J.A.; Bhutta, Z.; Gibson, R.S.; King, J.C.; Lönnerdal, B.; Ruel, M.T.; Sandström, B.; Wasantwisut, E.; Hotz, C. International Zinc Nutrition Consultative Group (IZiNCG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control. Food Nutr. Bull. 2004, 25 (Suppl. 2), S94–S203.
King, J.C. Determinants of maternal zinc status during pregnancy. Am. J. Clin. Nutr. 2000, 71, 1334S–1343S.
Maret, W. Zinc biochemistry, physiology, and homeostasis: Recent insights and current trends. BioMetals 2001, 14, 187–190.
Van Biervliet, S.; Van Biervliet, J.P.; Robberech, E.; Taylor, C. Importance of Zinc in Cystic Fibrosis Patients. Curr. Pediatr. Rev. 2009, 5, 184e8.
Ozutemiz, A.O.; Aydin, H.H.; Isler, M.; Celik, H.A.; Batur, Y. Effect of omeprazole on plasma zinc levels after oral zinc administration. Indian J. Gastroenterol. 2002, 21, 216–218.
Proesmans, M.; De Boeck, K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur. J. Pediatr. 2003, 162, 760–763.
Farrell, C.P.; Morgan, M.; Rudolph, D.S.; Hwang, A.; Albert, N.E.; Valenzano, M.C.; Wang, X.; Mercogliano, G.; Mullin, J.M. Proton Pump Inhibitors Interfere with Zinc Absorption and Zinc Body Stores. Gastroenterol. Res. 2011, 4, 243–251.
World Health Organization. C-Reactive Protein Concentrations as a Marker of Inflammation or Infection for Interpreting Biomarkers of Micronutrient Status; Vitamin and Mineral Nutrition Information System Inside; WHO/NMH/NHD/EPG/14.7; World Health Organization: Geneva, Switzerland, 2014; pp. 1–4.
Prasad, A.S. Laboratory diagnosis of zinc deficiency. J. Am. Coll. Nutr. 1985, 4, 591–598.
Singh, A.; Smoak, B.L.; Patterson, K.Y.; LeMay, L.G.; Veillon, C.; Deuster, P.A. Biochemical indices of selected trace minerals in men: Effect of stress. Am. J. Clin. Nutr. 1991, 53, 126–131.
Corbo, M.D.; Lam, J. Zinc deficiency and its management in the pediatric population: A literature review and proposed etiologic classification. J. Am. Acad. Dermatol. 2013, 69, 616–624.
Prentice, S. They are what you eat: Can nutritional factors during gestation and early infancy modulate the neonatal immune response? Front Immunol. 2017, 8, 1641.
Calder, P.; Prescott, S.; Caplan, M. Scientific Review: The Role of Nutrients in Immune Function of Infants and Young Children; Emerging Evidence for Long-Chain Polyunsaturated Fatty Acids; Mead Johnson & Company: Glenview, IL, USA, 2007.
Wintergerst, E.; Maggini, S.; Hornig, D. Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Ann. Nutr. Metab. 2006, 50, 85–94.
Brooks, W. Zinc for severe pneumonia in very young children: Double-blind placebo-controlled trial. Lancet 2004, 363, 1683–1688.
Van Biervliet, S.; Vande Velde, S.; Van Biervliet, J.P.; Robberecht, E. The effect of zinc supplements in cystic fibrosis patients. Ann. Nutr. Metab. 2008, 52, 152–156.
Sharma, G.; Lodha, R.; Shastri, S.; Saini, S.; Kapil, A.; Singla, M.; Mukherjee, A.; Jat, K.R.; Kabra, M.; Kabra, S.K. Zinc Supplementation for One Year Among Children with Cystic Fibrosis Does Not Decrease Pulmonary Infection. Respir. Care 2016, 61, 78–84.
Safai-Kutti, S.; Selin, E.; Larsson, S.; Jagenburg, R.; Denfors, I.; Sten, G.; Kjellmer, I. Zinc therapy in children with cystic fibrosis. Beiträge zur Infusionstherapie 1991, 27, 104–114.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Pediatrics; Nutrition & Dietetics

Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Marlene Fabiola Escobedo Monge

Enrique Barrado

Carmen Alonso Vicente

María Paz Redondo del Río

José Manuel Marugán de Miguelsanz

View Times: 554

Update Date: 19 Jan 2023

Table of Contents

Video Upload Options

Confirm

1. Introduction

2. Zinc Deficiency in in Patients with Cystic Fibrosis

References